Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled vs Oral Afatinib Dimaleate in Healthy Smokers
NCT06897735Phase 1Terminated
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of afatinib in lung cancer, oral cancer and melanoma (2 arms). Primary endpoints: Maximum observed plasma concentration at 48 hours and Afatinib dimaleate urinary concentrations at 96 hours. Started Nov 2025; status: terminated.
02
Drugs
afatinib
03
Conditions
lung canceroral cancermelanoma
Beyond the preview
Go deeper on NCT06897735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897735.